SINGLE-DOSE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF THE DUAL ENDOTHELIN RECEPTOR ANTAGONIST APROCITENTAN IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT.

被引：0
|
作者：
Fontes, M. [1 ]
Halabi, A. [2 ]
Tomaszewska-Kiecana, M. [3 ]
Dinge-Manse, J. [1 ]
Sidharta, P. [1 ]
机构：
[1] Idorsia Pharmaceut, Allschwil, Switzerland
[2] Clin Res Serv Kiel, Kiel, Germany
[3] Biokinet, Jozefow, Poland
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P-160
引用
收藏
页码：S47 / S48
页数：2
相关论文
共 50 条
  • [1] Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
    Fontes, Magda S. C.
    Dingemanse, Jasper
    Halabi, Atef
    Tomaszewska-Kiecana, Monika
    Sidharta, Patricia N.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [2] Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
    Magda S. C. Fontes
    Jasper Dingemanse
    Atef Halabi
    Monika Tomaszewska-Kiecana
    Patricia N. Sidharta
    Scientific Reports, 12
  • [3] Single-dose pharmacokinetics and tolerability of aprocitentan, a dual endothelin receptor antagonist, in subjects with severe renal function impairment
    Sidharta, P. N.
    Ulc, I.
    Dingemanse, J.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 : S92 - S92
  • [4] Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment
    Sidharta, Patricia N.
    Ulc, Ivan
    Dingemanse, Jasper
    CLINICAL DRUG INVESTIGATION, 2019, 39 (11) : 1117 - 1123
  • [5] Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment
    Patricia N. Sidharta
    Ivan Ulč
    Jasper Dingemanse
    Clinical Drug Investigation, 2019, 39 : 1117 - 1123
  • [6] Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects
    Fontes, Magda S. C.
    Dingemanse, Jasper
    Sidharta, Patricia N.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (07): : 718 - 725
  • [7] Single-and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
    Sidharta, Patricia N.
    Melchior, Meggane
    Kankam, Martin K.
    Dingemanse, Jasper
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 949 - 964
  • [8] MULTIPLE-DOSE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF APROCITENTAN, A DUAL ENDOTHELIN RECEPTOR ANTAGONIST, IN HEALTHY JAPANESE AND CAUCASIAN SUBJECTS.
    Sidharta, P.
    Dingemanse, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S43 - S44
  • [9] SINGLE-DOSE SAFETY AND PHARMACOKINETICS OF APIXABAN IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT
    Frost, C. E.
    Yu, Z.
    Wang, J.
    Li, T.
    Zeigler, C.
    Schuster, A.
    Ly, V.
    Zhang, D.
    LaCreta, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S34 - S34
  • [10] Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
    Akifumi Kurata
    Takafumi Yoshida
    Megumi Inoue
    Tomoko Ishizuka
    Takafumi Nakatsu
    Takako Shimizu
    Manabu Kato
    Yasuhiro Nishikawa
    Hitoshi Ishizuka
    Advances in Therapy, 2020, 37 : 253 - 264
12345